In a Kaplan–Meier analysis of the non‐MS cohort stratified into DSG2‐high and DSG2‐low groupings, the DSG2‐high group again had significantly poorer survival, with an almost four‐fold greater risk of dying compared to those who were categorized as DSG2‐low (HR 3.68, 95% CI 2.18–6.22, P < 0.001, Fig. 3F and Model 3 in Table S1). Here, DSG2 is linked to myeloid sarcoma.